SGLT2s are currently only approved for use in the U.S. for type 2 diabetes, but a lot of people with type 1 are taking them off label with positive results.
read more →
If your diabetes doctor thinks you should start insulin, it doesn’t mean you aren’t managing your condition well. You probably need to start insulin because your pancreas is failing, not you.
read more →
Did you know only 20% of people with diabetes have all three common conditions under control: A1c, blood pressure and cholesterol? One of the big reasons is medication adherence.
read more →
The newest classes of diabetes meds to treat type 2 are pulling more than double duty, helping to better control blood sugars, protect the heart, lower body weight and prevent chronic kidney disease.
read more →
SGLT-2 Inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflizin), are the newest class of oral medications for the treatment of type 2 diabetes. They’re generally well tolerated and associated with significant weight loss compared with other type 2 oral meds, but there are still precautions to consider.
read more →
